Skip to main content
. Author manuscript; available in PMC: 2022 Sep 3.
Published in final edited form as: Biochem J. 2016 Sep 13;473(22):4159–4172. doi: 10.1042/BCJ20160620

Figure 6. (l)-nebivolol suppresses CPVT in heterozygous RyR2-R4496C mutant mice.

Figure 6.

Representative ECG recordings of heterozygous RyR2-R4496C mutant mice treated with DMSO (control) (a) or (l)-nebivolol (2.0 mg/kg/day for 5 days) (b) before and 24 minutes after intraperitoneal injection of epinephrine (1.2 mg/kg) and caffeine (100 mg/kg). VT duration (%) in sequential 3-min period post-injection (c) and over the entire 30-min recording period post-injection (d) were measured in mice treated with (l)-nebivolol (0.4 mg/kg/day or 2.0 mg/kg/day) or DMSO (control). (e) Heart rate (pre-injection of epinephrine/caffeine) in mice treated with DMSO (control) or (l)-nebivolol (0.4 mg/kg/day or 2.0 mg/kg/day) as determined by ECG recordings. Data shown are means ± SEM (n=7–10; *P < 0.01 vs control).